Peter Schoch

Head of Jantar GmbH at Jantar GmbH

Speaker

Peter Schoch has studied biochemistry and promoted in biophysics at the ETH Zurich in 1980. After post-doc studies at the UCSD in the US he joined Roche in Basel where he worked for 16 years at various positions in preclinical and clinical pharmaceutical R&D. After three further assignments as i) Head of R&D and member of the Executive Board of a large cosmetics and personal care company in Switzerland (Mibelle AG), ii) Managing Director of a European Medical Society (ESCMID) and iii) Head of R&D in a startup for dermatological skin care he founded in 2015 Jantar GmbH. The objective of Jantar is to develop dicholine succinate (JT-1) as novel treatment of chronic rhinosinusitis. The status and achievements attained so far, i.e. the clinical results, the potential of the compound and the pending work, will be the subject of the presentation.